Progressive Muscular Atrophy
13
3
6
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 6 completed trials
Clinical Trials (13)
Digital Assessment of Speech and Fine Motor Control in ALS
Clinical Procedures to Support Research in ALS
TRIAL READY (Clinical Trial Readiness)
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
Phenotype, Genotype and Biomarkers 2
Comprehensive Analysis Platform To Understand, Remedy and Eliminate ALS
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Study of ALS Reversals 2: Genetic Analyses
Study of ALS Reversals 4: LifeTime Exposures
Answer ALS: Individualized Initiative for ALS Discovery
A Patient Centric Motor Neuron Disease Activities of Daily Living Scale
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
Levetiracetam for Cramps, Spasticity and Neuroprotection in Motor Neuron Disease